Environmental Factor, November 2010, National Institute of Environmental Health Sciences
Succimer found ineffective for removing mercury
By Robin Mackar
According to Walter Rogan, M.D., head of the Pediatric Epidemiology Group at the NIEHS, succimer - a drug used for treating lead poisoning - does not effectively remove mercury from the body. Rogan is a co-author on the paper that appears online (http://www.ncbi.nlm.nih.gov/pubmed/20889164) in the Journal of Pediatrics. ��
"Succimer is effective for treating children with lead poisoning, but it does not work very well for mercury," Rogan said. "Although it is not approved by the Food and Drug Administration to reduce mercury, succimer is reportedly being used for conditions like autism, in the belief that these conditions are caused, in part, by mercury poisoning. Our new data offers little support for this practice."
Most mercury exposure in the United States is from methylmercury, found in foods such as certain fish. Thimerosal, a preservative that was once more commonly used in vaccines, contains another form of mercury, called ethylmercury.
Although researchers found that succimer lowered blood concentrations of mercury after one week, continued therapy for five months only slowed the rate at which the children accumulated mercury. The safety of higher doses and longer courses of treatment has not been studied.
An earlier study provides the data
To conduct the study, the researchers used samples and data from an earlier clinical trial, led by NIEHS, called the Treatment of Lead-exposed Children (TLC) trial (http://www.niehs.nih.gov/research/atniehs/labs/epi/studies/tlc/index.cfm). In the TLC study, succimer lowered blood lead in 2-year-old children with moderate to high blood lead concentrations.
Using blood samples from 767 children who participated in the TLC trial, the researchers found that mercury concentrations were similar in all children before treatment and that during treatment, concentrations eventually increased in both groups, but more slowly in the children given succimer.
"Although succimer may slow the increase in blood mercury concentrations, such small changes seem unlikely to produce any clinical benefit," Rogan explained. He and his colleagues had reported in an earlier paper that succimer has few adverse side effects, mostly rashes, and an unexplained increase in injuries in children given succimer rather than placebo.
The subjects of the study did not have unusually high blood mercury concentrations for African-American children, and the study did not investigate where the mercury in the children came from.
Results are important for children's health
"This research fills a gap in the scientific literature that could not be addressed any other way. We were fortunate to have samples already collected from toddlers who had been treated with succimer for lead poisoning, allowing us to help answer this important question," said Linda Birnbaum, Ph.D., director of NIEHS and the National Toxicology Program.
Birnbaum noted NIH's commitment to supporting research that provides critically needed information that will help drive more prevention and treatment options for children with autism and other neurodevelopmental disorders.
The study was supported by the NIEHS Intramural Research Program, the National Institute for Minority Health and Health Disparities at NIH, and the National Center for Environmental Health at the Centers for Disease Control and Prevention. The succimer, Chemet, and the placebo, were gifts from McNeil Laboratories, Fort Washington, Pa.
Citation: Cao Y, Chen A, Jones RL, Radcliffe J, Dietrich KN, Caldwell KL, et al. (http://www.ncbi.nlm.nih.gov/pubmed/20889164) 2010. Efficacy of succimer chelation of mercury at background exposures in toddlers: a randomized trial. J Pediatr. Epub ahead of print. DOI:10.1016/j.jpeds.2010.08.036.
(Robin Mackar is the News Director in the NIEHS Office of Communications and Public Liaison and a regular contributor to the Environmental Factor.)